Ad
ASMB - Assembly Biosciences Stock Trading
About | Assembly Biosciences Inc. (NASDAQ:ASMB)
Not available
Quote | Assembly Biosciences Inc. (NASDAQ:ASMB)
| Last: | $0.85 |
|---|---|
| Change Percent: | 1.69% |
| Open: | $0.87 |
| Close: | $0.85 |
| High: | $0.885 |
| Low: | $0.82 |
| Volume: | 86,311 |
| Last Trade Date Time: | 10/02/2023 03:00:00 am |
News | Assembly Biosciences Inc. (NASDAQ:ASMB)
-
− ABI-6250 demonstrated low nanomolar potency against hepatitis D virus and selective inhibition of NTCP in preclinical studies with once-daily dosing projected – − Progression into clinical studies planned by the end of 2024 – SOUTH SAN FRANCISCO, Cali...
-
-- Two oral presentations and one poster will feature new data from the Company’s hepatitis B/hepatitis D entry inhibitor, capsid assembly modulator ABI-4334, and interferon-alpha receptor agonist programs -- SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Assembly Bi...
Message Board Posts | Assembly Biosciences Inc. (NASDAQ:ASMB)
| Subject | By | Source | When |
|---|---|---|---|
| ASBM abandons HBV arena, for all practical purposes: | DewDiligence | investorshub | 04/18/2023 5:57:44 PM |
| ASBM 4Q22 results12/31/22 cash=$92M(down_from $109M @9/30/22): | DewDiligence | investorshub | 03/22/2023 9:18:31 PM |
| ASMB halts development of ABI-H3733, an HBV core inhibitor: | DewDiligence | investorshub | 03/22/2023 9:17:28 PM |
| ASMB(+14%)reports_interim phase1/1b data_for HBV core inhibitors: | DewDiligence | investorshub | 12/19/2022 2:52:01 PM |
| whytestocks: $ASMB News Article - Assembly Biosciences Doses First Subject in Phase 1a Clinical Tria | whytestocks | investorshangout | 11/14/2022 6:10:52 PM |
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
Ad
-
− ABI-6250 demonstrated low nanomolar potency against hepatitis D virus and selective inhibition of NTCP in preclinical studies with once-daily dosing projected – − Progression into clinical studies planned by the end of 2024 – SOUTH SAN FRANCISCO, Cali...
-
-- Two oral presentations and one poster will feature new data from the Company's hepatitis B/hepatitis D entry inhibitor, capsid assembly mo...
-
-- Two oral presentations and one poster will feature new data from the Company’s hepatitis B/hepatitis D entry inhibitor, capsid assembly modulator ABI-4334, and interferon-alpha receptor agonist programs -- SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Assembly Bi...